Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced new clinical performance data for its ExoDx™ Lung(ALK) liquid biopsy test. The data demonstrated high sensitivity and specificity of the novel exosome-based liquid biopsy test in patients with non-small cell lung cancer (NSCLC) suspected to be positive for EML4-ALK translocations. Building upon a previously presented data set, the company also presented new data showing the ability of its proprietary exosomal RNA (exoRNA) plus cell-free DNA (cfDNA) platform to detect with high sensitivity EGFR activating mutations and the EGFR T790M resistance mutation in blood plasma of patients with NSCLC.